TNFR-associated factor 2 deficiency in b lymphocytes predisposes to chronic lymphocytic leukemia/small lymphocytic lymphoma in mice

Journal of Immunology

Volumn 189, Issue 2, 2012, Pages 1053-1061

  Pérez Chacón, Gema ^a   Llobet, David ^b,d   Pardo, Constanza ^a,e   Pindado, José ^b,f   Choi, Yongwon ^c   Reed, John C ^b   Zapata, Juan M ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b BURNHAM INSTITUTE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d Institute for Cancer Genetics   (United States)

^e Hospital Universitario Madrid Sanchinarro   (Spain)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAKPOINT CLUSTER REGION PROTEIN; CD40 ANTIGEN; CELLULAR INHIBITORS OF APOPTOSIS 1 PROTEIN; CELLULAR INHIBITORS OF APOPTOSIS 2 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN 2; INHIBITOR OF APOPTOSIS PROTEIN; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEASOME; PROTEIN BCL XL; PROTEIN P100; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; ENZYME ACTIVATION; GENE; GENE DELETION; GENE EXPRESSION; GENE TARGETING; IMMUNOPATHOGENESIS; LEUKEMOGENESIS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTOMA; MARGINAL ZONE LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SMALL LYMPHOCYTIC LYMPHOMA; SURVIVAL; TNFR ASSOCIATED FACTOR 2 DEFICIENCY; TRAF2 GENE; TRAF2DN GENE;

ANIMALS; B-LYMPHOCYTE SUBSETS; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, FOLLICULAR; MICE; MICE, TRANSGENIC; MUTATION; PROTEIN STRUCTURE, TERTIARY; TNF RECEPTOR-ASSOCIATED FACTOR 2; ZINC FINGERS;

EID: 84863628112     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1200814     Document Type: Article

References (52)

1. Zapata, J. M., V. Martínez-García, and S. Lefebvre. 2007. Phylogeny of the TRAF/MATH domain. Adv. Exp. Med. Biol. 597: 1-24.
2. Pineda, G., C. K. Ea, and Z. J. Chen. 2007. Ubiquitination and TRAF signaling. Adv. Exp. Med. Biol. 597: 80-92.
3. Ha, H., D. Han, and Y. Choi. 2009. TRAF-mediated TNFR-family signaling. Curr. Protoc. Immunol. Chapter 11:Unit11.9D.
4. Zapata, J. M., S. Lefebvre, and J. C. Reed. 2007. Targeting TRAfs for therapeutic intervention. Adv. Exp. Med. Biol. 597: 188-201.
5. Chiorazzi, N., and M. Ferrarini. 2011. Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities. Blood 117: 1781-1791.
6. Zapata, J. M., M. Krajewska, H. C. Morse, III, Y. Choi, and J. C. Reed. 2004. TNF receptor-associated factor (TRAF) domain and Bcl-2 cooperate to induce small B cell lymphoma/chronic lymphocytic leukemia in transgenic mice. Proc. Natl. Acad. Sci. USA 101: 16600-16605. (Pubitemid 39557759)
7. Zapata, J. M., M. Krajewska, S. Krajewski, S. Kitada, K. Welsh, A. Monks, N. McCloskey, J. Gordon, T. J. Kipps, R. D. Gascoyne, et al. 2000. TNFRassociated factor family protein expression in normal tissues and lymphoid malignancies. J. Immunol. 165: 5084-5096.
8. Grech, A. P., M. Amesbury, T. Chan, S. Gardam, A. Basten, and R. Brink. 2004. TRAF2 differentially regulates the canonical and noncanonical pathways of NF-kappaB activation in mature B cells. Immunity 21: 629-642. (Pubitemid 39487887)
9. Gardam, S., F. Sierro, A. Basten, F. Mackay, and R. Brink. 2008. TRAF2 and TRAF3 signal adapters act cooperatively to control the maturation and survival signals delivered to B cells by the BAFF receptor. Immunity 28: 391-401.
10. Lee, S. Y., A. Reichlin, A. Santana, K. A. Sokol, M. C. Nussenzweig, and Y. Choi. 1997. TRAF2 is essential for JNK but not NF-kappaB activation and regulates lymphocyte proliferation and survival. Immunity 7: 703-713. (Pubitemid 28156637)
11. Katsumata, M., R. M. Siegel, D. C. Louie, T. Miyashita, Y. Tsujimoto, P. C. Nowell, M. I. Greene, and J. C. Reed. 1992. Differential effects of Bcl-2 on T and B cells in transgenic mice. Proc. Natl. Acad. Sci. USA 89: 11376-11380.
12. Reed, J., L. Meister, M. Cuddy, C. Geyer, and D. Pleasure. 1991. Differential expression of the Bcl-2 proto-oncogene in neuroblastoma and other human tumor cell lines of neural origin. Cancer Res. 5l: 6529-6538.
13. Zapata, J. M., R. Takahashi, G. S. Salvesen, and J. C. Reed. 1998. Granzyme release and caspase activation in activated human T-lymphocytes. J. Biol. Chem. 273: 6916-6920. (Pubitemid 28160356)
14. Hostager, B. S., S. A. Haxhinasto, S. L. Rowland, and G. A. Bishop. 2003. Tumor necrosis factor receptor-associated factor 2 (TRAF2)-deficient B lymphocytes reveal novel roles for TRAF2 in CD40 signaling. J. Biol. Chem. 278: 45382-45390. (Pubitemid 37432675)
15. Brown, K. D., B. S. Hostager, and G. A. Bishop. 2002. Regulation of TRAF2 signaling by self-induced degradation. J. Biol. Chem. 277: 19433-19438. (Pubitemid 34967452)
16. Vince, J. E., D. Pantaki, R. Feltham, P. D. Mace, S. M. Cordier, A. C. Schmukle, A. J. Davidson, B. A. Callus, W. W. Wong, I. E. Gentle, et al. 2009. TRAF2 must bind to cellular inhibitors of apoptosis for tumor necrosis factor (tnf) to efficiently activate nf-kappab and to prevent tnf-induced apoptosis. J. Biol. Chem. 284: 35906-35915.
17. Lin, W. J., Y. W. Su, Y. C. Lu, Z. Hao, I. I. Chio, N. J. Chen, A. Brüstle, W. Y. Li, and T. W. Mak. 2011. Crucial role for TNF receptor-associated factor 2 (TRAF2) in regulating NFkB2 signaling that contributes to autoimmunity. Proc. Natl. Acad. Sci. USA 108: 18354-18359.
18. Guo, F., D. Weih, E. Meier, and F. Weih. 2007. Constitutive alternative NF-kappaB signaling promotes marginal zone B-cell development but disrupts the marginal sinus and induces HEV-like structures in the spleen. Blood 110: 2381-2389. (Pubitemid 47523158)
19. Enzler, T., G. Bonizzi, G. J. Silverman, D. C. Otero, G. F. Widhopf, A. Anzelon-Mills, R. C. Rickert, and M. Karin. 2006. Alternative and classical NF-kappa B signaling retain autoreactive B cells in the splenic marginal zone and result in lupus-like disease. Immunity 25: 403-415. (Pubitemid 44354213)
20. Gardam, S., V. M. Turner, H. Anderton, S. Limaye, A. Basten, F. Koentgen, D. L. Vaux, J. Silke, and R. Brink. 2011. Deletion of cIAP1 and cIAP2 in murine B lymphocytes constitutively activates cell survival pathways and inactivates the germinal center response. Blood 117: 4041-4051.
21. Csomos, R. A., C. W. Wright, S. Galbán, K. A. Oetjen, and C. S. Duckett. 2009. Two distinct signalling cascades target the NF-kappaB regulatory factor c-IAP1 for degradation. Biochem. J. 420: 83-91.
22. Csomos, R. A., G. F. Brady, and C. S. Duckett. 2009. Enhanced cytoprotective effects of the inhibitor of apoptosis protein cellular IAP1 through stabilization with TRAF2. J. Biol. Chem. 284: 20531-20539.
23. Silke, J., T. Kratina, D. Chu, P. G. Ekert, C. L. Day, M. Pakusch, D. C. Huang, and D. L. Vaux. 2005. Determination of cell survival by RING-mediated regulation of inhibitor of apoptosis (IAP) protein abundance. Proc. Natl. Acad. Sci. USA 102: 16182-16187. (Pubitemid 41688888)
24. Cheung, H. H., S. Plenchette, C. J. Kern, D. J. Mahoney, and R. G. Korneluk. 2008. The RING domain of cIAP1 mediates the degradation of RING-bearing inhibitor of apoptosis proteins by distinct pathways. Mol. Biol. Cell 19: 2729-2740.
25. Kress, C. L., M. Konopleva, V. Martínez-García, M. Krajewska, S. Lefebvre, M. L. Hyer, T. McQueen, M. Andreeff, J. C. Reed, and J. M. Zapata. 2007. Triterpenoids display single agent anti-tumor activity in a transgenic mouse model of chronic lymphocytic leukemia and small B cell lymphoma. PLoS ONE 2: e559.
26. Park, Y. C., V. Burkitt, A. R. Villa, L. Tong, and H. Wu. 1999. Structural basis for self-association and receptor recognition of human TRAF2. Nature 398: 533-538.
27. Li, X., Y. Yang, and J. D. Ashwell. 2002. TNF-RII and c-IAP1 mediate ubiquitination and degradation of TRAF2. Nature 416: 345-347.
28. Vallabhapurapu, S., A. Matsuzawa, W. Zhang, P. H. Tseng, J. J. Keats, H. Wang, D. A. Vignali, P. L. Bergsagel, and M. Karin. 2008. Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. Nat. Immunol. 9: 1364-1370.
29. Zarnegar, B. J., Y. Wang, D. J. Mahoney, P. W. Dempsey, H. H. Cheung, J. He, T. Shiba, X. Yang, W. C. Yeh, T. W. Mak, et al. 2008. Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nat. Immunol. 9: 1371-1378.
30. Conze, D. B., Y. Zhao, and J. D. Ashwell. 2010. Non-canonical NF-κB activation and abnormal B cell accumulation in mice expressing ubiquitin protein ligaseinactive c-IAP2. PLoS Biol. 8: e1000518.
31. Sasaki, Y., D. P. Calado, E. Derudder, B. Zhang, Y. Shimizu, F. Mackay, S. Nishikawa, K. Rajewsky, and M. Schmidt-Supprian. 2008. NIK over-expression amplifies, whereas ablation of its TRAF3-binding domain replaces BAFF:BAFF-R-mediated survival signals in B cells. Proc. Natl. Acad. Sci. USA 105: 10883-10888.
32. Enzler, T., A. P. Kater, W. Zhang, G. F. Widhopf, II, H. Y. Chuang, J. Lee, E. Avery, C. M. Croce, M. Karin, and T. J. Kipps. 2009. Chronic lymphocytic leukemia of Emu-TCL1 transgenic mice undergoes rapid cell turnover that can be offset by extrinsic CD257 to accelerate disease progression. Blood 114: 4469-4476.
33. Zhang, W., A. P. Kater, G. F. Widhopf, II, H. Y. Chuang, T. Enzler, D. F. James, M. Poustovoitov, P. H. Tseng, S. Janz, C. Hoh, et al. 2010. B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA 107: 18956-18960.
34. Mackay, F., and P. Schneider. 2009. Cracking the BAFF code. Nat. Rev. Immunol. 9: 491-502.
35. Zhang, B., Z. Wang, T. Li, E. N. Tsitsikov, and H. F. Ding. 2007. NF-kappaB2 mutation targets TRAF1 to induce lymphomagenesis. Blood 110: 743-751. (Pubitemid 47105413)
36. Kim, K. E., C. Gu, S. Thakur, E. Vieira, J. C. Lin, and A. B. Rabson. 2000. Transcriptional regulatory effects of lymphoma-associated NFKB2/lyt10 protooncogenes. Oncogene 19: 1334-1345. (Pubitemid 30160626)
37. Wang, Z., B. Zhang, L. Yang, J. Ding, and H. F. Ding. 2008. Constitutive production of NF-kappaB2 p52 is not tumorigenic but predisposes mice to inflammatory autoimmune disease by repressing Bim expression. J. Biol. Chem. 283: 10698-10706.
38. Pillai, S., A. Cariappa, and S. T. Moran. 2005. Marginal zone B cells. Annu. Rev. Immunol. 23: 161-196. (Pubitemid 40563168)
39. Scielzo, C., B. Apollonio, L. Scarfò, A. Janus, M. Muzio, E. Ten Hacken, P. Ghia, and F. Caligaris-Cappio. 2011. The functional in vitro response to CD40 ligation reflects a different clinical outcome in patients with chronic lymphocytic leukemia. Leukemia 25: 1760-1767.
40. Grzybowska-Izydorczyk, O., B. Cebula, T. Robak, and P. Smolewski. 2010. Expression and prognostic significance of the inhibitor of apoptosis protein (IAP) family and its antagonists in chronic lymphocytic leukaemia. Eur. J. Cancer 46: 800-810.
41. Kitada, S., J. M. Zapata, M. Andreeff, and J. C. Reed. 2000. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 96: 393-397. (Pubitemid 30463354)
42. Kater, A. P., F. Dicker, M. Mangiola, K. Welsh, R. Houghten, J. Ostresh, A. Nefzi, J. C. Reed, C. Pinilla, and T. J. Kipps. 2005. Inhibitors of XIAP sensitize CD40-activated chronic lymphocytic leukemia cells to CD95-mediated apoptosis. Blood 106: 1742-1748. (Pubitemid 41208589)
43. Loeder, S., T. Zenz, A. Schnaiter, D. Mertens, D. Winkler, H. Döhner, K. M. Debatin, S. Stilgenbauer, and S. Fulda. 2009. A novel paradigm to trigger apoptosis in chronic lymphocytic leukemia. Cancer Res. 69: 8977-8986.
44. Fabbri, G., S. Rasi, D. Rossi, V. Trifonov, H. Khiabanian, J. Ma, A. Grunn, M. Fangazio, D. Capello, S. Monti, et al. 2011. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J. Exp. Med. 208: 1389-1401.
45. Rossi, D., S. Deaglio, D. Dominguez-Sola, S. Rasi, T. Vaisitti, C. Agostinelli, V. Spina, A. Bruscaggin, S. Monti, M. Cerri, et al. 2011. Alteration of BIRC3 and multiple other NF-κB pathway genes in splenic marginal zone lymphoma. Blood 118: 4930-4934.
46. Keats, J. J., R. Fonseca, M. Chesi, R. Schop, A. Baker, W. J. Chng, S. Van Wier, R. Tiedemann, C. X. Shi, M. Sebag, et al. 2007. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 12: 131-144. (Pubitemid 47208626)
47. Annunziata, C. M., R. E. Davis, Y. Demchenko, W. Bellamy, A. Gabrea, F. Zhan, G. Lenz, I. Hanamura, G. Wright, W. Xiao, et al. 2007. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12: 115-130. (Pubitemid 47199123)
48. Puente, X. S., M. Pinyol, V. Quesada, L. Conde, G. R. Ordóñez, N. Villamor, G. Escaramis, P. Jares, S. Beà, M. González-Díaz, et al. 2011. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 475: 101-105.
49. Wang, L., M. S. Lawrence, Y. Wan, P. Stojanov, C. Sougnez, K. Stevenson, L. Werner, A. Sivachenko, D. S. DeLuca, L. Zhang, et al. 2011. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N. Engl. J. Med. 365: 2497-2506.
50. Thomas, G. S., L. Zhang, K. Blackwell, and H. Habelhah. 2009. Phosphorylation of TRAF2 within its RING domain inhibits stress-induced cell death by promoting IKK and suppressing JNK activation. Cancer Res. 69: 3665-3672.
51. Zheng, C., V. Kabaleeswaran, Y. Wang, G. Cheng, and H. Wu. 2010. Crystal structures of the TRAF2: cIAP2 and the TRAF1: TRAF2: cIAP2 complexes: affinity, specificity, and regulation. Mol. Cell 38: 101-113.
52. Lee, S. Y., and Y. Choi. 2007. TRAF1 and its biological functions. Adv. Exp. Med. Biol. 597: 25-31.